Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Sagimet Biosciences Inc.NASDAQ: SGMT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.84M rose 24.9% year over year, ahead of the +13.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at +50.8% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24.9% holds above the trailing-twelve-month pace of +13.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.45M USD
- Year-over-year change
- +22.0%
- 4-year CAGR
- +35.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.45M | +22.0% |
| FY2024 | 2024-12-31 | 5.29M | +6.0% |
| FY2023 | 2023-12-31 | 4.99M | +165.4% |
| FY2022 | 2022-12-31 | 1.88M | -1.3% |
| FY2021 | 2021-12-31 | 1.9M | — |
Stock-Based Compensation vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 stock-based compensation of $6.82M is the 8th largest of the 11 companies compared; the peer median is $10.88M.
- Its year-over-year change of +13.6% is the 4th highest of 11, against a peer median of -7.7%.
- Over three fiscal years its annual growth of +50.8% compares with a peer median of +16.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
ZURAZura Bio Limited | LTM Mar 2026 | $11.32M | -37.2% | +233.0% | — |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $6.82M | +13.6% | +50.8% | — |
| LTM Mar 2026 | $5.84M | -6.8% | +38.9% | — | |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding SGMT) | $10.88M | -7.7% | +16.5% | 44.1% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Change in Working Capital | (55K) | 4.21M | (978K) | (1.05M) | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 120K | (907K) | 929K |
| Other Working Capital | (55K) | 4.21M | (1.1M) | (141K) | (1.98M) |
| Other Non-Cash Items | 883K | (215K) | 98K | (1.11M) | (8K) |
| Operating Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (41.45M) | (19.62M) | (108.09M) | (106.86M) |
| Sales of Investments | 0 | 9.44M | 32.2M | 46.4M | 111.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (32.01M) | 12.58M | (61.68M) | 4.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 12K | 89.68M | 105.75M | 275K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.07M) | (85K) | (3.51M) | (931K) | 0 |
| Financing Cash Flow | 9.74M | (73K) | 86.17M | 104.82M | 275K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.97M) | (56.57M) | 74.98M | 701K | (40.82M) |
| Free Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.